These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 28522916)

  • 61. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Regulatory T-cell responses in chronic hepatitis B patients treated with nucleos(t)ide analogs compared with healthy subjects and untreated infected individuals.
    Chen LY; Zhu LY; Yang BS; Bi MR; Yan BZ; Wang W; Ma YJ
    Hepatogastroenterology; 2012; 59(120):2582-6. PubMed ID: 22626879
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
    Xu Z; Chen LB; Cao H; Shu X; Xu QH; Li G; Xie QF
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Jun; 24(3):224-6. PubMed ID: 21186534
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
    An J; Lim YS; Kim GA; Han SB; Jeong W; Lee D; Shim JH; Lee HC; Lee YS
    BMC Gastroenterol; 2017 Jan; 17(1):15. PubMed ID: 28103819
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Yang Q; Gong ZJ; Hu DF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
    Yim HJ; Lee HJ; Suh SJ; Seo YS; Kim CW; Lee CD; Park SH; Lee MS; Park CK; Chae HB; Kim MY; Baik SK; Kim YS; Kim JH; Lee JI; Lee JW; Hong SP; Um SH
    Intervirology; 2014; 57(5):239-47. PubMed ID: 24993731
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
    Ling N; Zhou Z; Zhang DZ; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
    Tsai MC; Lee CM; Chiu KW; Hung CH; Tung WC; Chen CH; Tseng PL; Chang KC; Wang JH; Lu SN; Yen YH; Hu TH
    J Antimicrob Chemother; 2012 Mar; 67(3):696-9. PubMed ID: 22174039
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Lamivudine and adefovir resistance in a patient with HBeAg negative chronic hepatitis B].
    Mateos ML; Tato M; Moreira V
    Gastroenterol Hepatol; 2006 Feb; 29(2):71-3. PubMed ID: 16448607
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ; George J; Strasser SI; Lee AU; Sievert W; Nicoll AJ; Desmond PV; Roberts SK; Locarnini S; Bowden S; Angus PW
    Gut; 2011 Feb; 60(2):247-54. PubMed ID: 21036792
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).
    Lee HW; Park JY; Kim BK; Kim MY; Lee JI; Kim YS; Yoon KT; Han KH; Ahn SH
    Clin Mol Hepatol; 2016 Dec; 22(4):443-449. PubMed ID: 27880997
    [TBL] [Abstract][Full Text] [Related]  

  • 76. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.
    Huang YW; Takahashi S; Tsuge M; Chen CL; Wang TC; Abe H; Hu JT; Chen DS; Yang SS; Chayama K; Kao JH
    Antivir Ther; 2015; 20(4):369-75. PubMed ID: 24739420
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
    Piratvisuth T; Komolmit P; Tanwandee T; Sukeepaisarnjaroen W; Chan HL; Pessôa MG; Fassio E; Ono SK; Bessone F; Daruich J; Zeuzem S; Cheinquer H; Pathan R; Dong Y; Trylesinski A
    PLoS One; 2013; 8(2):e54279. PubMed ID: 23390496
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies.
    Kim HS; Yim HJ; Jang MK; Park JW; Suh SJ; Seo YS; Kim JH; Kim BH; Park SJ; Lee SH; Kim SG; Kim YS; Lee JI; Lee JW; Kim IH; Kim TY; Kim JW; Jeong SH; Jung YK; Park H; Hwang SG;
    World J Gastroenterol; 2015 Oct; 21(38):10874-82. PubMed ID: 26478678
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
    J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.